Details for Patent: 7,772,209
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 7,772,209 protect, and when does it expire?
Patent 7,772,209 protects PEMFEXY and ALIMTA and is included in two NDAs.
Protection for ALIMTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eighteen patent family members in eleven countries.
Summary for Patent: 7,772,209
Title: | Antifolate combination therapies |
Abstract: | A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent. |
Inventor(s): | Niyikiza; Clet (Indianapolis, IN) |
Assignee: | Eli Lilly and Company (Indianapolis, IN) |
Application Number: | 11/776,329 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,772,209 |
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 7,772,209
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eagle Pharms | PEMFEXY | pemetrexed | SOLUTION;INTRAVENOUS | 209472-001 | Feb 8, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH MESOTHELIOMA | See Plans and Pricing | ||||
Eagle Pharms | PEMFEXY | pemetrexed | SOLUTION;INTRAVENOUS | 209472-001 | Feb 8, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER | See Plans and Pricing | ||||
Lilly | ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462-002 | Sep 7, 2007 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Lilly | ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462-001 | Feb 4, 2004 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,772,209
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 359823 | See Plans and Pricing | |||
Australia | 6968801 | See Plans and Pricing | |||
Cyprus | 1107649 | See Plans and Pricing | |||
Germany | 60127970 | See Plans and Pricing | |||
Denmark | 1313508 | See Plans and Pricing | |||
European Patent Office | 1313508 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |